Honeybear Biosciences Strengthens Global Scientific Presence through AACR, Biologics World Taiwan, and BioAsia
Honeybear Biosciences continued to elevate its international scientific profile through a series of presentations at the American Association for Cancer Research (AACR) Annual Meeting, Biologics Taiwan, and BioAsia, showcasing the innovation and global competitiveness of its proprietary CoNectar® site-specific conjugation platform for next-generation antibody conjugates.
The company's international outreach began at the AACR Annual Meeting, where Honeybear presented its latest research on next-generation antibody conjugates, highlighting the broad applicability of the CoNectar® platform in advancing precision oncology. The presentation attracted strong interest from researchers and industry professionals, further strengthening Honeybear's visibility within the global cancer research community.
Following AACR, Dr. Simon Shih-Hsien Chuang, Chief Executive Officer of Honeybear Biosciences, was invited to be the moderator in some keynote sessions and to speak at Biologics World Taiwan, where he delivered a presentation on the company's CoNectar® site-specific conjugation platform and its application in developing next-generation antibody-drug conjugates (ADCs) and antibody-radionuclide conjugates (ARCs). Dr. Chuang highlighted how precise site-specific conjugation, controlled drug-to-antibody ratios (DAR), and flexible payload design can enhance therapeutic efficacy, improve manufacturability, and support the development of differentiated antibody conjugates for global markets.
Building on this momentum, Honeybear was invited to participate in BioAsia's Special Forum – "Next-Generation ADCs," featuring two keynote presentations. Dr. Michael Evans, Professor of Radiology and Biomedical Imaging at the University of California, San Francisco (UCSF), presented "Chemical Strategies to Expand the Therapeutic Window for Radiopharmaceutical Therapy," discussing emerging chemical strategies to maximize the therapeutic benefits through the innovative radiopharmaceuticals’ design. Dr. Simon Shih-Hsien Chuang then delivered "Site-Specific Dual-Payload Antibody Conjugation Enhances Antitumor Efficacy," demonstrating how Honeybear's proprietary CoNectar® platform enables precise site-specific conjugation, controlled DAR, and dual-payload design to enhance antitumor efficacy while addressing drug resistance. Honeybear Biosciences has demonstrated the promising potential of next-generation ADCs/ ARCs developed through its core technology platform.
Through its esposures in AACR, Biologics Taiwan, and BioAsia, Honeybear Biosciences strengthened collaborations with leading academic institutions, pharmaceutical companies, and strategic partners worldwide, further enhancing the international recognition of Taiwan's biotechnology innovation. Leveraging its proprietary CoNectar® platform, the company remains committed to advancing next-generation ADC and ARC therapeutics and bringing innovative precision medicines to cancer patients worldwide.
Honeybear Biosciences continued to elevate its international scientific profile through a series of presentations at the American Association for Cancer Research (AACR) Annual Meeting, Biologics Taiwan, and BioAsia, showcasing the innovation and global competitiveness of its proprietary CoNectar® site-specific conjugation platform for next-generation antibody conjugates.
The company's international outreach began at the AACR Annual Meeting, where Honeybear presented its latest research on next-generation antibody conjugates, highlighting the broad applicability of the CoNectar® platform in advancing precision oncology. The presentation attracted strong interest from researchers and industry professionals, further strengthening Honeybear's visibility within the global cancer research community.
Following AACR, Dr. Simon Shih-Hsien Chuang, Chief Executive Officer of Honeybear Biosciences, was invited to be the moderator in some keynote sessions and to speak at Biologics World Taiwan, where he delivered a presentation on the company's CoNectar® site-specific conjugation platform and its application in developing next-generation antibody-drug conjugates (ADCs) and antibody-radionuclide conjugates (ARCs). Dr. Chuang highlighted how precise site-specific conjugation, controlled drug-to-antibody ratios (DAR), and flexible payload design can enhance therapeutic efficacy, improve manufacturability, and support the development of differentiated antibody conjugates for global markets.
Building on this momentum, Honeybear was invited to participate in BioAsia's Special Forum – "Next-Generation ADCs," featuring two keynote presentations. Dr. Michael Evans, Professor of Radiology and Biomedical Imaging at the University of California, San Francisco (UCSF), presented "Chemical Strategies to Expand the Therapeutic Window for Radiopharmaceutical Therapy," discussing emerging chemical strategies to maximize the therapeutic benefits through the innovative radiopharmaceuticals’ design. Dr. Simon Shih-Hsien Chuang then delivered "Site-Specific Dual-Payload Antibody Conjugation Enhances Antitumor Efficacy," demonstrating how Honeybear's proprietary CoNectar® platform enables precise site-specific conjugation, controlled DAR, and dual-payload design to enhance antitumor efficacy while addressing drug resistance. Honeybear Biosciences has demonstrated the promising potential of next-generation ADCs/ ARCs developed through its core technology platform.
Through its esposures in AACR, Biologics Taiwan, and BioAsia, Honeybear Biosciences strengthened collaborations with leading academic institutions, pharmaceutical companies, and strategic partners worldwide, further enhancing the international recognition of Taiwan's biotechnology innovation. Leveraging its proprietary CoNectar® platform, the company remains committed to advancing next-generation ADC and ARC therapeutics and bringing innovative precision medicines to cancer patients worldwide.
Under the leadership of Dr. Simon Shih-Hsien Chuang, Chief Executive Officer, the company's latest research has been presented at leading international biotechnology conferences, including the American Association for Cancer Research (AACR) Annual Meeting, Biologics World Taiwan, and BioAsia. These presentations underscore the innovative capabilities of the proprietary CoNectar® platform and its growing international visibility.
